As previously disclosed, on October 5, 2020, Eidos Therapeutics, Inc., (the “Company” or “Eidos”), entered into an Agreement and Plan of Merger with BridgeBio Pharma, Inc., a Delaware corporation, Globe Merger Sub I, Inc. and Globe Merger Sub II, Inc. Upon the consummation of the Mergers, each of Suzanne Hooper, Neil Kumar, William Lis, Douglas “Duke” Rohlen, Ali Satvat and Uma Sinha ceased to be directors of the Company. Additionally, effective as of the Effective Time, Jonathan Barr and Cameron Turtle became directors of the Company.